130954-99-3

Upstream product

• 3800-06-4 2-amino-4'-fluorobenzophenone 
• 36239-09-5 ethyl chlorocarbonylacetate 

Downstream Products

• 130048-16-7 (E)-7-[2-Dimethylamino-4-(4-fluoro-phenyl)-quinolin-3-yl]-3,5-dihydroxy-hept-6-enoic acid ethyl ester 
• 391681-88-2 ethyl 4-(4-fluorophenyl)-2-methylthio-3-quinolinecarboxylate 
• 391681-93-9 4-(4-fluorophenyl)-2-(N-ethyl-N-methylamino)-3-quinolinecarboxaldehyde 
• 391681-87-1 methyl 4-(4-fluorophenyl)-2-methoxy-3-quinolinecarboxylate 
• 391681-90-6 4-(4-fluorophenyl)-2-methylthio-3-quinolinemethanol 
• 391681-89-3 4-(4-fluorophenyl)-2-methoxy-3-quinolinemethanol 

Relevant academic research and scientific papers

Inhibitors of Cholesterol Biosynthesis. 4. trans-6-tetrahydro-4-hydroxy-2H-pyran-2-ones, a Novel Series of HMG-CoA Reductase Inhibitors

A series of substituted quinoline mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and (cholesterol biosynthesis) in vivo.Since previous studies suggested that the 4-(4-fluorophenyl) and 2-(1-methylethyl) substituents afforded optimum potency, attention was focused on variations at position 6 of the quinoline ring.Biological evaluation of a small number of analogues bearing a variety of 6-substituents showed that modification at this position had little effect on potency.Several compounds (8b, 8e, and 11) were identified that showed comparable potency to compaction and mevinolin in both the in vitro and in vivo assays.

6-(2-(2-(SUBSTITUTED AMINO)-3-QUINOLINYL) ETHENYL AND ETHYL) TETRAHYDRO-4-HYDROXYPYRAN-2-ONE INHIBITORS OF CHOLESTEROL BIOSYNTHESIS

Novel 6-[2-[2-(substituted amino)-3-quinolinyl]-ethenyl and ethyl] tetrahydro-4-hydroxypyran-2-ones and/or oxides and the corresponding dihydroxy ring opened acids and esters are described, as well as methods for the preparation and pharmaceutical composi